COVID-19 has caused significant social and economic disruptions around the world. As quickly as the coronavirus has spread, scientists from all corners of the world have attempted to keep pace with testing investigational new drugs and vaccines as well as repurposing old therapies. This session will review the most recent clinical evidence for the agents that have received FDA approval, emergency use authorization (EUA) as well as those in close contention for FDA analysis. In addition, a brief overview of some of the major consensus guidelines for COVID-19 treatment will be reviewed. Lastly, current recommendations for the development, distribution, and prioritization of vaccine administration will be discussed.

Learning Objectives

At the completion of this activity, participants should be able to:

  1. Summarize the evidence for key therapeutic options that have been evaluated for use in the treatment of COVID-19.
  2. Discuss the evidence for vaccine options being used to prevent COVID-19.
  3. Discuss the Centers for Disease Control and Prevention interim clinical considerations for use as well as prioritization of vaccines currently authorized in the U.S.

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.